Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03QHC
|
|||
| Former ID |
DIB016695
|
|||
| Drug Name |
KAF156
|
|||
| Indication | Malaria [ICD-11: 1F40-1F45; ICD-10: B50-B64, B54] | Phase 2 | [1] | |
| Company |
Novartis pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H23F2N5O
|
|||
| Canonical SMILES |
CC1(C2=NC(=C(N2CCN1C(=O)CN)NC3=CC=C(C=C3)F)C4=CC=C(C=C4)F)C
|
|||
| InChI |
1S/C22H23F2N5O/c1-22(2)21-27-19(14-3-5-15(23)6-4-14)20(26-17-9-7-16(24)8-10-17)28(21)11-12-29(22)18(30)13-25/h3-10,26H,11-13,25H2,1-2H3
|
|||
| InChIKey |
BUPRVECGWBHCQV-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1261113-96-5
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01753323) Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.